compounded semaglutide crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounders maintain a firm grip

So when one of our physicians or nurse practitioners sees a patient with obesity and we are prescribing, deprescribing, managing side effects or addressing abnormal laboratory values, we work with the PCP, we communicate with the PCP to try to create a coordinated approach so that the patient is getting excellent primary care to address the multitude of clinical conditions that they may have, while also receiving excellent specialty care to manage this underlying complicated disease state

The FDA concern is not just lack of approval

Skin Goals Assessment Our expert dermatologists assess your skin goals and condition to determine the optimal glutathione concentration for maximum effectiveness

The April 1, 2026 release applies to services April 1 through September 30, 2026

Late gadolinium enhancement (LGE) with cardiac magnetic resonance (CMR) is a marker of myocardial fibrosis of any etiology 8